Affiliation:
1. Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu
2. University of Rome Tor Vergata Department of Industrial Engineering: Universita degli Studi di Roma Tor Vergata Dipartimento di Ingegneria Industriale
Abstract
Abstract
Background: Multiple Breath washout (MBW) represents an important tool to detect early a possible pulmonary exacerbation especially in Cystic Fibrosis (CF) disease. Lung clearance index (LCI) is the most commonly reported multiple breath washout (MBW) index and in the last years was used as management measure for evaluation. Our aim was to analyze clinical utility of LCI index variability in pulmonary exacerbation in CF after intravenous (IV) antibiotic therapy.
Methods: A single-center study was conducted at CF Unit of Bambino Gesù Children’s Hospital among hospitalized > 3 years patients for pulmonary exacerbations and treated with antibiotic IV treatment for 14 days. MBW and spirometry were evaluated within 72 hours of admission to hospital and at the end of hospitalization. Descriptive analysis was conducted and correlations between quantitative variables were investigated.
Results: Fifty-seven patients (M22/F35) with an average age 18.56 (± 8.54) years were enrolled. LCI2.5 was significantly reduced at the end of antibiotic treatment in both pediatric and adult populations with an average reduction of -6,99%; 37/57 patients denoted an improvement, 20/57 are stable or worsened in LCI2.5 values and 4/57 (7.02%) had a significant deterioration (>15%) at end of treatment. On the contrary a significative elevation of FEV1% and FVC% were found, respectively of +7,30% and of +5,46%. A positive good correlection among LCI 2.5 and Scond (rho= +0,615, p=0.000) and LCI 2.5 and Sacin (rho=+0,649, p=0.000) and a negative strong correlation between FEV1% and LCI 2.5 were found in post treatment period. A similar modification of LCI 2.5 and FEV1 was noticed in both adult and pediatric population.
Conclusions: LCI may have a role in the routine clinical care of both adult and pediatric CF patients as a good tool to assess response to IV antibiotic end-therapy in the same way as FEV1.
Publisher
Research Square Platform LLC
Reference34 articles.
1. Hospital for Sick Children, Toronto;Cystic fibrosis mutation database;Accessed September,2018
2. Stoltz A, Meyerholz DA, Welsh DKJ. MJ, Origins of cystic fibrosis lung disease N Engl J Med 2015 Jan 22;372(4):351 – 62.
3. Effect of body posture on gas distribution in the lungs;Bouhuys A;J Appl Physiol
4. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial;Sutharsan S;Lancet Respir Med
5. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles;Graeber SY;Am J Respir Crit Care Med 2022